The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one ...
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback